Rule 2.7, 3.10.3, 3.10.4, 3.10.5
Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12, 04/03/13
Name of entity |
Starpharma Holdings Limited |
ABN |
20 078 532 180 |
We (the entity) give ASX the following information.
You must complete the relevant sections (attach sheets if there is not enough space).
1 | +Class of +securities issued or to be issued | Ordinary Shares |
2 | Number of +securities issued or to be issued (if known) or maximum number which may be issued | 2,623,361 Ordinary Shares |
3 | Principal terms of the +securities (e.g. if options, exercise price and expiry date; if partly paid +securities, the amount outstanding and due dates for payment; if +convertible securities, the conversion price and dates for conversion) | Ordinary fully paid shares |
4 | Do the +securities rank equally in all respects from the +issue date with an existing +class of quoted +securities? If the additional +securities do not rank equally, please state:
| Yes |
5 | Issue price or consideration | $0.73 per share (total $1,915,000) |
6 | Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets) | Share Purchase Plan announced 9 December 2015: Working capital to progress the development activities of the company |
6a | Is the entity an +eligible entity that has obtained security holder approval under rule 7.1A? If Yes, complete sections 6b - 6h in relation to the +securities the subject of this Appendix 3B, and comply with section 6i | No |
6b | The date the security holder resolution under rule 7.1A was passed | N/A |
6c | Number of +securities issued without security holder approval under rule 7.1 | N/A |
6d | Number of +securities issued with security holder approval under rule 7.1A | N/A |
6e | Number of +securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting) | N/A | |
6f | Number of +securities issued under an exception in rule 7.2 | N/A | |
6g | If +securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the +issue date and both values. Include the source of the VWAP calculation. | N/A | |
6h | If +securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements | N/A | |
6i | Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A - complete Annexure 1 and release to ASX Market Announcements | N/A | |
7 | +Issue dates Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A. Cross reference: item 33 of Appendix 3B. | 22 January 2016 | |
Number | +Class | ||
8 | Number and +class of all +securities quoted on ASX (including the +securities in section 2 if applicable) | 367,064,289 | Ordinary Shares |
Number | +Class |
8,006,746 Nil 8,006,746 | Performance RightsLast notice Lapsed since last notice Performance Rights (SPLAK) |
Number and +class of all
+securities not quoted on ASX (including the +securities in section 2 if applicable)
Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)
11 | Is security holder approval required? | N/A |
12 | Is the issue renounceable or non- renounceable? | |
13 | Ratio in which the +securities will be offered | |
14 | +Class of +securities to which the offer relates | |
15 | +Record date to determine entitlements | |
16 | Will holdings on different registers (or subregisters) be aggregated for calculating entitlements? | |
17 | Policy for deciding entitlements in relation to fractions | |
18 | Names of countries in which the entity has security holders who will not be sent new offer documents Note: Security holders must be told how their entitlements are to be dealt with. Cross reference: rule 7.7. | |
19 | Closing date for receipt of acceptances or renunciations |
Starpharma Holdings Limited issued this content on 2016-01-22 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 2016-01-22 00:14:03 UTC
Original Document: http://www.starpharma.com/assets/asxannouncements/160122_Appendix_3B___SPP.pdf